Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYN101 in Healthy Subjects and Postmenopausal Women With Low Bone Mass
NCT07178327Phase 1Active, not recruiting
- Start
- Sep 2025
- Primary completion
- Mar 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Osteoporotic fracture comparing LYN101 with Placebo (2 arms). Primary endpoint: Adverse Events at Day 175. Started Sep 2025; status: active, not recruiting.
02
Drugs
LYN101
03
Conditions
Osteoporotic fracture
Beyond the preview
Go deeper on NCT07178327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07178327.